[Discussion] dose-response looked steeper than anything else in the class and that cuts both ways
dose-response looked steeper than anything else in the class and that cuts both ways, and I am aware this is a minority view on this board. Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish. Phase 2 estimates…
What do you think the glucagon component is adding, specifically?
Push back: quoting the phase 2 headline as an expected outcome is not a fair reading of a small trial with wide intervals.
not approved anywhere, which is the single most important fact in this board
Yes — the comparison threads are apples to oranges and they generate more heat than anything else here.
Same read. The energy-expenditure mechanism is the interesting bit and it is not established in humans at scale.
Sent a vial to PeptideMeter out of curiosity. Result was 97.5% against a claimed 97.0%, which is the first independent number I had seen for this compound anywhere.
triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part